View Post

USPSTF recommends preventive drugs for women at high breast cancer risk

In Clinical Trials by Barbara Jacoby

By: Nelson HD, et al. JAMA. 2019;doi:10.1001/jama.2019.5780. Pace, LE, et al. JAMA. 2019;doi:10.1001/jama.2019.9689. USPSTF. JAMA. 2019;doi:10.1001/jama.2019.11885. From: healio.com The U.S. Preventive Services Task Force today recommended that clinicians offer breast cancer risk-reducing medications such as tamoxifen, raloxifene and aromatase inhibitors to asymptomatic women aged 35 years and older who are at elevated risk for developing the disease and low risk …

View Post

Why Patients Avoid Clinical Trials

In Clinical Trials by Barbara Jacoby

By: Cynthia Verst, PH.D., President, Design and Delivery Innovation R&D Development Solutions, IQVIA From: pharmavoice.com And how big data, analytics, technology and domain expertise can help change the paradigm The pharma industry has a big challenge when it comes to clinical trials, one that continues to hinder the industry’s approach to research. Sponsors want patients to enroll in their trials, …

View Post

Outsourcing in clinical trials: an EU struggle? – Data report analysis

In Clinical Trials by Barbara Jacoby

By: Claudette Hodge From: knect365.com In the collaborative environment of clinical trials, partnerships and outsourcing are essential, yet can open the door to a world of day-to-day challenges. In our recent State of the Industry Report 2019, we investigated what today’s clinical trials professionals see as the most prominent risks faced in managing relationships with third-party organisations. The survey was …

View Post

Many clinical trials for new cancer drugs didn’t include any data on race

In Clinical Trials by Barbara Jacoby

By: Megan Thielking From: statnews.com One-third of the clinical trials that led to new cancer drugs approved between 2008 and 2018 didn’t report on the race of trial participants — and even studies that did report on race often had far fewer black and Hispanic cancer patients than might be expected, given the makeup of the cancer patient population.That’s according …

View Post

Optimal Just-in-Time Service Changing the Paradigm of Cancer Trials

In Clinical Trials by Barbara Jacoby

From: businesswire.com First-patient-in milestone achieved in only two weeks with Cancer Treatment Centers of America Optimal Just-in-Time, a service of PPD’s Accelerated Enrollment Solutions (AES) business unit, and Cancer Treatment Centers of America® (CTCA) are collaborating to speed patient enrollment in oncology clinical trials, enhancing patient access to potentially life-changing therapies and saving time in drug researchers’ quest to conquer …

View Post

In a small study, a cancer vaccine assist beats immunotherapy drugs alone

In Clinical Trials by Barbara Jacoby

By: Sharon Begley From: statnews.com The largest study to date of a “cancer vaccine” plus one of the immunotherapy drugs that has revolutionized cancer treatment found that they kept patients’ tumors in check longer, on average, than drugs alone, but that the benefit was still only a few months for two forms of cancer, study sponsor Neon Therapeutics reported on …

View Post

Leveraging Patient-Centric Data Analytics to Accelerate Clinical Trials

In Clinical Trials by Barbara Jacoby

By: Crystal Black, Saama Technologies From: pharmavoice.com We are all familiar with the figures — it takes over a decade and $2.6 billion to bring a new drug to market. While these objective statistics are daunting and do give pause, almost every life science professional will agree that they don’t begin to tell the true story of the human element …

View Post

Sorry Princess Leia, but a Clinical Trial is My Only Hope

In Clinical Trials by Barbara Jacoby

By: Sarah DeBord From: curetoday.com I have two perspectives as I look at clinical trials: as the patient needing one and as an advocate encouraging patients to enroll in them. But how can I encourage someone to do something that I personally find so frustrating? Sarah DeBord was diagnosed with metastatic colon cancer at age 34. In the years since, …

View Post

IACS and other platforms develop new cancer treatments for clinical trials

In Clinical Trials by Barbara Jacoby

By: Clayton R. Boldt, Ph.D. From: mdanderson.org Therapeutics Discovery scientists bring clinical cancer research to the lab and use unique model for drug development to benefit cancer patients. “From the bench to the bedside” is a phrase often used to describe a drug discovery’s journey from the laboratory to the clinic, where patients benefit. MD Anderson’s Therapeutics Discovery division, however, …

View Post

EnGeneIC Announces First Patients with Advanced-Stage Pancreatic Cancer Dosed in Phase 1/2a Clinical Study of Targeted Cytotoxic Immunotherapy

In Clinical Trials by Barbara Jacoby

Source: EnGeneIC Limited From: prnewswire.com EnGeneIC Limited, a clinical-stage biopharmaceutical company advancing its proprietary EDV™ nanocell platform for targeted cyto-immunotherapy in cancer, today announced that the first four patients have been dosed in a Phase 1/2a study using the Company’s tumor-targeting, immunogenic EDVs™ to deliver a cytotoxic drug payload directly to tumors of patients who have exhausted curative treatment options. The …